Primary Analysis of ZUMA-2 Treatment of BTK Inhibitor-Naive Relapsed Refractory Mantle ...

ZUMA-2 study, cohort 3, showed durable responses to brexucabtagene autoleucel in BTK inhibitor–naive mantle cell lymphoma patients, with 91% objective response rate and 73% complete response at 15.5 months median follow-up. No new safety signals detected.


Related News

Primary Analysis of ZUMA-2 Treatment of BTK Inhibitor-Naive Relapsed Refractory Mantle ...

ZUMA-2 study, cohort 3, showed durable responses to brexucabtagene autoleucel in BTK inhibitor–naive mantle cell lymphoma patients, with 91% objective response rate and 73% complete response at 15.5 months median follow-up. No new safety signals detected.

© Copyright 2024. All Rights Reserved by MedPath